{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    30,
    31,
    40,
    46,
    51,
    53,
    54
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 0.8,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_4",
        "affectedSection": "Section 1.3.3.2 - Study GS-US-426-3988",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated preliminary safety and pharmacokinetic data for GS-0976 in subjects with hepatic impairment."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_4",
        "affectedSection": "Section 1.4.3.2 - Study GS-US-402-3885",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated status and disposition for the Phase 1 hepatic impairment study of GS-9674."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_4",
        "affectedSection": "Section 1.6.2 - Rationale for Dose Selection of GS-0976",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Refined the rationale for dosing in compensated cirrhosis based on updated exposure margins from hepatic impairment studies."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_4",
        "reasonText": "Integration of emerging Phase 1 data regarding hepatic impairment to support the safety and dosing rationale of the investigational products in subjects with advanced fibrosis.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_4",
        "reasonText": "Update study status and preliminary safety results from ongoing combination and single-agent trials (GS-US-426-3988 and GS-US-402-3885).",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3.3.2",
        "beforeText": "Not explicitly provided in snippet (Ongoing study description)",
        "afterText": "As of 17 November 2017, a total of 36 subjects were dosed; 34 subjects had completed study treatment. No subjects prematurely discontinued study treatment.",
        "summary": "Updated subject disposition and preliminary safety results for GS-0976 hepatic impairment study."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.6.2",
        "beforeText": "Not explicitly provided in snippet (Previous exposure margin estimates)",
        "afterText": "GS-0976 exposures in subjects with mild hepatic impairment (CP A) are expected to remain ≥22 and ≥105-fold lower than the GS-0976 exposures observed at the NOAELs.",
        "summary": "Updated exposure margin calculations relative to NOAEL based on preliminary PK data in mild hepatic impairment."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_4",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.4.3.2.1",
        "beforeText": "Not explicitly provided in snippet",
        "afterText": "One subject prematurely discontinued study treatment due to quality issues at the site that justified a suspension in dosing at the site.",
        "summary": "Clarified reason for a single subject discontinuation in the GS-9674 Phase 1 study."
      }
    ],
    "summary": {
      "impactCount": 3,
      "reasonCount": 2,
      "changeCount": 3
    }
  }
}